LT2480552T - 2'-fluoru pakeisti karbanukleozidų analogai, skirti antivirusiniam gydymui - Google Patents
2'-fluoru pakeisti karbanukleozidų analogai, skirti antivirusiniam gydymuiInfo
- Publication number
- LT2480552T LT2480552T LTEP10763083.2T LT10763083T LT2480552T LT 2480552 T LT2480552 T LT 2480552T LT 10763083 T LT10763083 T LT 10763083T LT 2480552 T LT2480552 T LT 2480552T
- Authority
- LT
- Lithuania
- Prior art keywords
- nucleoside analogs
- fluoro substituted
- antiviral treatment
- substituted carba
- carba
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 239000002777 nucleoside Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
-
- G—PHYSICS
- G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
- G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
- G03C7/00—Multicolour photographic processes or agents therefor; Regeneration of such processing agents; Photosensitive materials for multicolour processes
- G03C7/30—Colour processes using colour-coupling substances; Materials therefor; Preparing or processing such materials
- G03C7/32—Colour coupling substances
- G03C7/36—Couplers containing compounds with active methylene groups
- G03C7/38—Couplers containing compounds with active methylene groups in rings
- G03C7/381—Heterocyclic compounds
- G03C7/382—Heterocyclic compounds with two heterocyclic rings
- G03C7/3825—Heterocyclic compounds with two heterocyclic rings the nuclei containing only nitrogen as hetero atoms
- G03C7/3835—Heterocyclic compounds with two heterocyclic rings the nuclei containing only nitrogen as hetero atoms four nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24429709P | 2009-09-21 | 2009-09-21 | |
| PCT/US2010/049471 WO2011035231A1 (en) | 2009-09-21 | 2010-09-20 | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2480552T true LT2480552T (lt) | 2017-02-10 |
Family
ID=43031517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP10763083.2T LT2480552T (lt) | 2009-09-21 | 2010-09-20 | 2'-fluoru pakeisti karbanukleozidų analogai, skirti antivirusiniam gydymui |
Country Status (32)
| Country | Link |
|---|---|
| EP (2) | EP2480552B1 (lt) |
| JP (3) | JP5795766B2 (lt) |
| KR (2) | KR101818779B1 (lt) |
| CN (1) | CN102596958A (lt) |
| AP (1) | AP2012006189A0 (lt) |
| AU (4) | AU2010295373B2 (lt) |
| BR (3) | BR112012006261B1 (lt) |
| CA (1) | CA2773772C (lt) |
| CL (1) | CL2012000707A1 (lt) |
| CR (2) | CR20190103A (lt) |
| CY (1) | CY1118605T1 (lt) |
| DK (1) | DK2480552T3 (lt) |
| EA (1) | EA201200525A1 (lt) |
| EC (1) | ECSP12011817A (lt) |
| ES (2) | ES2614651T3 (lt) |
| HR (1) | HRP20170197T1 (lt) |
| HU (1) | HUE032252T2 (lt) |
| IL (2) | IL218599A (lt) |
| LT (1) | LT2480552T (lt) |
| ME (1) | ME02656B (lt) |
| MX (1) | MX352646B (lt) |
| NZ (1) | NZ599402A (lt) |
| PE (3) | PE20160217A1 (lt) |
| PL (1) | PL2480552T3 (lt) |
| PT (1) | PT2480552T (lt) |
| RS (1) | RS55699B1 (lt) |
| SG (1) | SG179194A1 (lt) |
| SI (1) | SI2480552T1 (lt) |
| SM (2) | SMT201700091T1 (lt) |
| UA (1) | UA110466C2 (lt) |
| WO (1) | WO2011035231A1 (lt) |
| ZA (1) | ZA201202175B (lt) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3237884B2 (ja) | 1991-12-27 | 2001-12-10 | 株式会社コーセー | 美爪料 |
| KR101645742B1 (ko) | 2008-04-23 | 2016-08-04 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료를 위한 카바-뉴클레오사이드 유사체 |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
| EP2671888A1 (en) | 2008-12-23 | 2013-12-11 | Gilead Pharmasset LLC | 3',5'-cyclic nucleoside phosphate analogues |
| AR074897A1 (es) | 2008-12-23 | 2011-02-23 | Pharmasset Inc | Fosforamidatos de nucleosidos |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| HRP20130862T1 (hr) | 2009-09-21 | 2013-10-25 | Gilead Sciences, Inc. | Procesi i intermedijeri za pripravu analoga 1'-cijanokarbanukleozida |
| US7973013B2 (en) * | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| DK2480552T3 (en) * | 2009-09-21 | 2017-02-20 | Gilead Sciences Inc | 2 'FLUOROUS-SUBSTITUTED CARBA NUCLEOSIDE ANALYSIS FOR ANTIVIRAL TREATMENT |
| US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| WO2011123645A2 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Nucleoside phosphoramidates |
| TW201201815A (en) * | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
| WO2012012465A1 (en) | 2010-07-19 | 2012-01-26 | Clarke, Michael, O'neil Hanrahan | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| AU2011280910B2 (en) | 2010-07-22 | 2015-07-09 | Gilead Sciences, Inc. | Methods and compounds for treating Paramyxoviridae virus infections |
| TW201305185A (zh) * | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之２’－氟取代之碳－核苷類似物 |
| WO2012039791A1 (en) * | 2010-09-20 | 2012-03-29 | Gilead Sciences, Inc. | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
| EA201691695A1 (ru) | 2010-11-19 | 2017-11-30 | Джилид Сайэнс, Инк. | Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат |
| EP2654900A1 (en) | 2010-12-20 | 2013-10-30 | Gilead Sciences, Inc. | Combinations for treating hcv |
| TW201329096A (zh) * | 2011-09-12 | 2013-07-16 | Idenix Pharmaceuticals Inc | 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物 |
| PL2709613T5 (pl) | 2011-09-16 | 2020-12-14 | Gilead Pharmasset Llc | Metody leczenia hcv |
| WO2013056046A1 (en) | 2011-10-14 | 2013-04-18 | Idenix Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| EA028928B9 (ru) * | 2012-03-13 | 2018-05-31 | Джилид Сайэнс, Инк. | 2'-замещенные карбануклеозидные аналоги для противовирусного лечения |
| WO2014059902A1 (en) * | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | 2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases |
| EP2909209B1 (en) * | 2012-10-17 | 2022-08-03 | Merck Sharp & Dohme LLC | 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases |
| AR092959A1 (es) | 2012-10-17 | 2015-05-06 | Merck Sharp & Dohme | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales |
| US9732111B2 (en) | 2012-11-19 | 2017-08-15 | Merck Sharp & Dohme Corp. | 2′-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| MY172166A (en) | 2013-01-31 | 2019-11-15 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| EP3010512B1 (en) | 2013-06-18 | 2017-12-27 | Merck Sharp & Dohme Corp. | Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| UA119050C2 (uk) | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
| US10683321B2 (en) | 2013-12-18 | 2020-06-16 | Idenix Pharmaceuticals Llc | 4′-or nucleosides for the treatment of HCV |
| TWI678369B (zh) | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類 |
| US10526363B2 (en) | 2014-08-15 | 2020-01-07 | Merck Sharp & Dohme Corp. | Substituted phosphoramidate compounds and uses thereof |
| TWI673283B (zh) | 2014-08-21 | 2019-10-01 | 美商基利科學股份有限公司 | ２’－氯胺基嘧啶酮及嘧啶二酮核苷類 |
| TWI698444B (zh) | 2014-10-29 | 2020-07-11 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| PL3236972T3 (pl) | 2014-12-26 | 2022-03-07 | Emory University | Przeciwwirusowe pochodne n4-hydroksycytydyny |
| WO2016160646A1 (en) | 2015-04-02 | 2016-10-06 | Merck Sharp & Dohme Corp. | Process for making phosphoramidate protected nucleoside compounds |
| CN104945437B (zh) * | 2015-05-19 | 2017-03-01 | 广州诺威生物技术有限公司 | 一种嘧啶类新化合物 |
| HRP20220355T1 (hr) | 2015-09-16 | 2022-05-13 | Gilead Sciences, Inc. | Postupci za liječenje infekcija coronaviridae |
| TWI740910B (zh) * | 2016-03-09 | 2021-10-01 | 美商艾洛斯生物製藥公司 | 非環抗病毒劑 |
| CN114456175B (zh) | 2016-03-28 | 2024-09-03 | 因赛特公司 | 作为tam抑制剂的吡咯并三嗪化合物 |
| CN106083962B (zh) * | 2016-06-08 | 2018-12-18 | 成都倍特药业有限公司 | 一种具有环磷酰胺结构的化合物及其制备方法 |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| EP3484886B1 (en) * | 2016-07-14 | 2020-03-04 | Hoffmann-La Roche AG | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| US20190169221A1 (en) * | 2016-08-12 | 2019-06-06 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| EP4331677A3 (en) | 2017-03-14 | 2024-05-29 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| CA3178212A1 (en) | 2017-05-01 | 2018-11-08 | Gilead Sciences, Inc. | Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| TW201919648A (zh) | 2017-07-11 | 2019-06-01 | 美商基利科學股份有限公司 | 用於治療病毒感染之含rna聚合酶抑制劑與環糊精的組合物 |
| EA202090775A1 (ru) * | 2017-09-18 | 2020-07-06 | Янссен Байофарма, Инк. | Замещенные нуклеозиды, нуклеотиды и их аналоги |
| GB2581936B (en) | 2017-12-07 | 2021-02-10 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
| KR20210125026A (ko) * | 2019-02-07 | 2021-10-15 | 베이진 엘티디 | Tlr7 작용제로서의 이미다조[2,1-f][1,2,4]트리아진-4-아민 유도체 |
| WO2020227421A1 (en) | 2019-05-09 | 2020-11-12 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
| CN114641299A (zh) | 2020-01-27 | 2022-06-17 | 吉利德科学公司 | 用于治疗SARS CoV-2感染的方法 |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI791193B (zh) | 2020-02-18 | 2023-02-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI874791B (zh) | 2020-02-18 | 2025-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| AR121356A1 (es) | 2020-02-18 | 2022-05-11 | Gilead Sciences Inc | Compuestos antivirales |
| JP7554841B2 (ja) | 2020-03-12 | 2024-09-20 | ギリアード サイエンシーズ， インコーポレイテッド | １’－シアノヌクレオシドを調製する方法 |
| EP4132651A1 (en) | 2020-04-06 | 2023-02-15 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| TW202203941A (zh) | 2020-05-29 | 2022-02-01 | 美商基利科學股份有限公司 | 瑞德西韋之治療方法 |
| PE20230618A1 (es) | 2020-06-24 | 2023-04-14 | Gilead Sciences Inc | Analogos de nucleosido de 1'-ciano y usos de los mismos |
| PL4204421T3 (pl) | 2020-08-27 | 2024-09-16 | Gilead Sciences, Inc. | Związki i sposoby leczenia zakażeń wirusowych |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| WO2022219636A1 (en) * | 2021-04-14 | 2022-10-20 | Yeda Research And Development Co. Ltd. | Anti-viral and anti-tumoral compounds, and uses thereof |
| ES3028915T3 (en) | 2021-04-16 | 2025-06-20 | Gilead Sciences Inc | Methods of preparing carbanucleosides using amides |
| WO2022238816A1 (en) * | 2021-05-14 | 2022-11-17 | Bm Pharma Consulting Pty. Ltd | Bicyclic heterocyclic compounds for prophylaxis and treatment of viral infections |
| JP2024532166A (ja) | 2021-08-18 | 2024-09-05 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物並びにその製造方法及び使用方法 |
| IL315102A (en) | 2022-03-02 | 2024-10-01 | Gilead Sciences Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| DK0533833T3 (da) | 1990-06-13 | 1996-04-22 | Arnold Glazier | Phosphorprolægemidler |
| DE10399025I2 (de) | 1990-09-14 | 2007-11-08 | Acad Of Science Czech Republic | Wirkstoffvorläufer von Phosphonaten |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| DE19912636A1 (de) | 1999-03-20 | 2000-09-21 | Aventis Cropscience Gmbh | Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel |
| WO2001032153A2 (en) | 1999-11-04 | 2001-05-10 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| JP2003523978A (ja) | 2000-02-18 | 2003-08-12 | シャイアー・バイオケム・インコーポレイテッド | ヌクレオシドアナログを用いるｆｌａｖｉｖｉｒｕｓ感染の処置もしくは予防するための方法 |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| CA2426187C (en) | 2000-10-18 | 2011-08-16 | Pharmasset Limited | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation |
| JP2004532184A (ja) | 2001-01-22 | 2004-10-21 | メルク エンド カムパニー インコーポレーテッド | Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体 |
| EP1438054A4 (en) | 2001-09-28 | 2006-07-26 | Idenix Cayman Ltd | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION |
| KR20050088079A (ko) | 2002-11-15 | 2005-09-01 | 이데닉스 (케이만) 리미티드 | 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이 |
| CA2580457C (en) | 2004-09-14 | 2014-11-04 | Pharmasset, Inc. | Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
| CN101043893A (zh) * | 2004-10-21 | 2007-09-26 | 默克公司 | 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷 |
| AU2005317081A1 (en) * | 2004-10-21 | 2006-06-22 | Merck & Co., Inc. | Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection |
| WO2006116557A1 (en) * | 2005-04-25 | 2006-11-02 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
| WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
| WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
| CA2627839C (en) | 2005-11-02 | 2014-08-19 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| WO2008005542A2 (en) * | 2006-07-07 | 2008-01-10 | Gilead Sciences, Inc., | Antiviral phosphinate compounds |
| US20080261913A1 (en) * | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| WO2008085508A2 (en) | 2007-01-05 | 2008-07-17 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| HRP20120758T1 (hr) * | 2007-01-12 | 2012-10-31 | Biocryst Pharmaceuticals, Inc. | Antiviralni nukleozidni analozi |
| US8188272B2 (en) | 2007-03-21 | 2012-05-29 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| JP2011513195A (ja) | 2007-05-10 | 2011-04-28 | バイオクライスト ファーマシューティカルズ， インコーポレイテッド | ウイルス感染およびがんの処置に使用するためのテトラヒドロフロ［３，４−ｄ］ジオキソラン化合物 |
| US8227431B2 (en) * | 2008-03-17 | 2012-07-24 | Hetero Drugs Limited | Nucleoside derivatives |
| KR101645742B1 (ko) * | 2008-04-23 | 2016-08-04 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료를 위한 카바-뉴클레오사이드 유사체 |
| EP2313102A2 (en) * | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| HRP20130862T1 (hr) * | 2009-09-21 | 2013-10-25 | Gilead Sciences, Inc. | Procesi i intermedijeri za pripravu analoga 1'-cijanokarbanukleozida |
| DK2480552T3 (en) * | 2009-09-21 | 2017-02-20 | Gilead Sciences Inc | 2 'FLUOROUS-SUBSTITUTED CARBA NUCLEOSIDE ANALYSIS FOR ANTIVIRAL TREATMENT |
-
2010
- 2010-09-20 DK DK10763083.2T patent/DK2480552T3/en active
- 2010-09-20 BR BR112012006261-1A patent/BR112012006261B1/pt active IP Right Grant
- 2010-09-20 PE PE2016000070A patent/PE20160217A1/es unknown
- 2010-09-20 RS RS20170152A patent/RS55699B1/sr unknown
- 2010-09-20 ME MEP-2017-35A patent/ME02656B/me unknown
- 2010-09-20 PL PL10763083T patent/PL2480552T3/pl unknown
- 2010-09-20 SM SM20170091T patent/SMT201700091T1/it unknown
- 2010-09-20 CR CR20190103A patent/CR20190103A/es unknown
- 2010-09-20 HR HRP20170197TT patent/HRP20170197T1/hr unknown
- 2010-09-20 ES ES10763083.2T patent/ES2614651T3/es active Active
- 2010-09-20 BR BR122021012877A patent/BR122021012877B8/pt active IP Right Grant
- 2010-09-20 ES ES16196457T patent/ES2730805T3/es active Active
- 2010-09-20 UA UAA201204937A patent/UA110466C2/ru unknown
- 2010-09-20 KR KR1020127010076A patent/KR101818779B1/ko active Active
- 2010-09-20 CA CA2773772A patent/CA2773772C/en active Active
- 2010-09-20 SG SG2012018883A patent/SG179194A1/en unknown
- 2010-09-20 WO PCT/US2010/049471 patent/WO2011035231A1/en active Application Filing
- 2010-09-20 AU AU2010295373A patent/AU2010295373B2/en active Active
- 2010-09-20 PE PE2020000354A patent/PE20210668A1/es unknown
- 2010-09-20 EP EP10763083.2A patent/EP2480552B1/en active Active
- 2010-09-20 SI SI201031372T patent/SI2480552T1/sl unknown
- 2010-09-20 CN CN201080041902XA patent/CN102596958A/zh active Pending
- 2010-09-20 KR KR1020187000491A patent/KR20180006499A/ko not_active Ceased
- 2010-09-20 JP JP2012529958A patent/JP5795766B2/ja active Active
- 2010-09-20 PT PT107630832T patent/PT2480552T/pt unknown
- 2010-09-20 HU HUE10763083A patent/HUE032252T2/en unknown
- 2010-09-20 EA EA201200525A patent/EA201200525A1/ru unknown
- 2010-09-20 PE PE2012000359A patent/PE20120995A1/es not_active Application Discontinuation
- 2010-09-20 EP EP16196457.2A patent/EP3150608B1/en active Active
- 2010-09-20 MX MX2012003391A patent/MX352646B/es active IP Right Grant
- 2010-09-20 BR BR122021021135-3A patent/BR122021021135B1/pt active IP Right Grant
- 2010-09-20 AP AP2012006189A patent/AP2012006189A0/xx unknown
- 2010-09-20 LT LTEP10763083.2T patent/LT2480552T/lt unknown
- 2010-09-20 NZ NZ599402A patent/NZ599402A/en unknown
-
2012
- 2012-03-13 IL IL218599A patent/IL218599A/en active IP Right Grant
- 2012-03-21 CL CL2012000707A patent/CL2012000707A1/es unknown
- 2012-03-23 ZA ZA2012/02175A patent/ZA201202175B/en unknown
- 2012-04-17 CR CR20120186A patent/CR20120186A/es unknown
- 2012-04-19 EC ECSP12011817 patent/ECSP12011817A/es unknown
-
2015
- 2015-05-14 JP JP2015098728A patent/JP6033362B2/ja active Active
-
2016
- 2016-09-28 IL IL248110A patent/IL248110A0/en unknown
- 2016-10-24 JP JP2016207475A patent/JP2017075146A/ja not_active Withdrawn
- 2016-11-23 AU AU2016262676A patent/AU2016262676B2/en active Active
-
2017
- 2017-02-07 CY CY20171100168T patent/CY1118605T1/el unknown
- 2017-02-09 SM SM201700091T patent/SMT201700091B/it unknown
-
2018
- 2018-06-20 AU AU2018204449A patent/AU2018204449B2/en active Active
-
2020
- 2020-04-17 AU AU2020202600A patent/AU2020202600B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL248110A0 (en) | Analogues of carba-nucleoside that are converted at the 2-position in fluorine for antiviral treatment | |
| HUS2000055I1 (hu) | 1'-szubsztituált carba-nukleozid analógok antivirális kezelésre | |
| AP3699A (en) | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | |
| AP2922A (en) | Carbra-nucleoside analogs for antiviral treatment | |
| SI2576534T1 (sl) | 1'-substituirana-karba-nukleozidna predzdravila za antivirusno zdravljenje | |
| HK1181678A (en) | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment | |
| HK1182103A (en) | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment | |
| TH0901001785B (th) | สารคล้ายคาร์บา-นิวคลิโอไซด์ที่ถูกแทนที่ที่ตำแหน่ง 1' สำหรับการบำบัดต้านไวรัส |